Dyadic's Stock Jumps On COVID-19 Vaccine Development Pact In India

Dyadic International Inc DYAI has collaborated with India-based Syngene International Limited to develop a COVID-19 vaccine candidate.
The company says that the vaccine can potentially provide protection against the emerging variants and can be manufactured affordably, at an enormous scale, using Dyadic's proprietary C1-cell protein production platform.
Dyadic will work with Syngene to develop a vaccine candidate to immunize people against current and future variants of the COVID-19 virus.
Price Action: DYAI shares are up 11.9% at $4.33 during the premarket session on the last check Wednesday.

Momentum48.20

Growth-

Quality-

Value19.60

Short

Medium

Long